Information on community-acquired bacterial bloodstream infections (BSIs) in individuals infected with human immunodeficiency virus (HIV) is limited. We conducted a systematic literature review. The case fraction of community-acquired bacterial BSIs in hospitalized patients is 20% and 30% in adults and children, respectively, compared to 9% in HIV-negative adults and children. Worldwide, the main pathogens of communityacquired BSI are nontyphoid salmonellae (NTS), Streptococcus pneumoniae, Escherichia coli, and Staphylococcus aureus, but regional differences are apparent, especially for S. pneumoniae. Compared to HIV-negative populations, HIV patients are particularly at risk to develop NTS bacteremia. Bacteremia incidence is related to immunosuppression, and antiretroviral therapy reduces the incidence of BSI in HIV patients (rate ratios, 0.63-0.02). Mortality rates varied between 7% and 46%. These results suggest that bacterial BSI is more likely to be found in HIV-positive than in HIV-negative patients upon hospitalization, and that causative pathogens vary by region.
The disease spectrum of human immunodeficiency virus (HIV)-positive patients differs in many ways from that of HIV-negative individuals. Before the introduction of antiretroviral therapy (ART), HIV patients suffered mainly from opportunistic infections. Treatment with ART resulted in a dramatic reduction in these opportunistic infections [1] . However, invasive bacterial infections continue to be an important cause of morbidity and mortality in HIV patients [2] [3] [4] [5] . HIV infection is often cited as a risk factor for bacterial bloodstream infections (BSIs), in particular with nontyphoid salmonellae (NTS) and Streptococcus pneumoniae [6] [7] [8] [9] . Sepsis resulting from bacterial infection is now a more frequent cause of intensive care unit (ICU) admission than Pneumocystis jiroveci pneumonia, accounting for 33% of ICU admissions in HIV patients [10, 11] . In addition, 2 cohorts demonstrated that bacterial infections account for 15% of mortality among HIV patients in the United States [5] .
We systematically analyze the relative risk of HIVinfected patients to present with community-acquired (CA) bacterial BSIs and the causative pathogens in HIV-positive populations. In addition, we describe the impact of ART, risk factors, and outcome in HIVpositive patients with CA BSI. Our epidemiological overview is organized according to age and geographic region.
METHODS
For this systematic review, we followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [12] .
Search Strategy and Selection Criteria
Two major scientific databases were searched (PubMed and Embase) with the search string "(HIV or AIDS) and (sepsis OR bloodstream infection OR bacteremia)." Results were limited to human studies and the English or French language. We conducted our study from May 2012, with a final literature search accomplished on April 2013. All abstracts and titles published between January 1996 and April 2013 were reviewed. By abstract review, we selected articles relevant to our subject. Case reports, conference abstracts, reviews, outpatient-based studies, and articles exclusively on fungal or mycobacterial infections were excluded from further analysis. Studies targeting specific groups, such as surgical patients and pregnant women, and studies exclusively on individual pathogens were also excluded.
During full text review, we selected articles that corresponded to our inclusion criteria. To study the differences in prevalence of BSI and its causative pathogens between HIV-positive and HIV-negative populations, studies were required to be prospective, to evaluate all admissions or all febrile presentations, to systematically perform blood cultures and HIV testing, and to stratify blood culture results by HIV status. To obtain information on which pathogens cause BSI in HIV patients, the impact of ART on the epidemiology of BSIs, and outcome, we also included retrospective studies and studies without an HIV-negative comparison group. Retrospective studies were required to have a sample size of at least 100 patients, to differentiate between nosocomial and CA infections and to provide clear information on HIV status and the isolated pathogens. However, studies that did not differentiate between nosocomial and CA infections were eligible if at least 80% of the infections were CA. Among the selected studies, only those that reported on the usage of ART among study participants were used to determine the impact of ART.
Data Extraction
Data were extracted and entered into an Excel database for aggregate analyses. Data entry was performed by the first author and cross-checked by the second author. For papers with combined data on bacterial, mycobacterial, and fungal infections, only the information on bacterial infections was used for this review.
Statistical Analysis
To compare the differential prevalence of bacterial BSI and determine differences in causative pathogens and mortality rates according to HIV status, odds ratios (ORs) were calculated. The significance of all ORs, using a 95% confidence interval (CI), was calculated using Fisher exact test. To analyze the influence of ART on the occurrence of CA BSIs, we calculated incidence rate ratios with a 95% CI [13] . To determine the prevalence of specific pathogens in HIV-positive patients, we calculated averages for each pathogen only on the fraction of studies that reported on them. Studies that did not report on a certain pathogen were left out of the average instead of taking a default value such as zero. We used GraphPad Prism (GraphPad Software, La Jolla, California) for statistical analyses and creation of figures.
RESULTS

Selection of Studies
Our search yielded 5202 hits, including 1643 duplicates ( Figure 1 ). During title and abstract review, 3468 articles were excluded on the grounds of having a focus other than bacterial BSIs in HIV patients, or based on study design or study population. From the remaining 91 articles, we selected 16 studies to determine the relative risk of HIV patients to present with bacterial BSIs (Tables 1 and 2 ) [2, 15-20, 25, 26, 29, 33, 37-39, 42] .
To determine the main causative pathogens in HIV patients and to study the impact of ART, we included 15 additional prospective and retrospective articles (Tables 1 and 2 ) [14, 21-24, 27, 28, 30-32, 34-36, 40, 43] .
Relative Risk of Bacterial BSI in HIV Patients
In all prospective adult case-control studies combined [2, 15-20, 25, 26, 29, 33, 37] 3) . One exception is a study in Tanzanian adults that indicated a trend toward a reduced risk in HIV patients, attributed to a significant protective effect of HIV infection against Salmonella Typhi infection [20] .
Influence of ART
Six studies reported on the impact of ART on the incidence of CA BSIs in HIV patients (Table 3 ) [24, 25, 28, 36, 38, 43] . All studies documented a decreased incidence of bacterial BSIs in HIV patients after the introduction of ART, with rate ratios comparing post-ART to pre-ART illness between 0.02 and 0.63. One of these, a Ugandan cohort study, demonstrated an increased rate of bacterial BSIs in patients in the first year after starting ART (rate ratio, 1.85), followed by a decline in the subsequent period to a level below the rate found in HIV patients without treatment (rate ratio, 0.56) [25] . However, even in patients treated with ART, the number of bacterial BSIs remained All prospective observational studies (POSs) and cohort studies with an HIV-negative comparison group (POS+ and cohort study+) were used to analyze the differences in prevalence of bacterial BSI between HIVpositive and HIV-negative hospitalized patients. Studies with an alternative study design were included for additional information on causative pathogens, the influence of highly active antiretroviral therapy, and mortality in HIV patients. Abbreviations: BSI, bloodstream infection; CA, community-acquired; CoNS, coagulase-negative Staphylococcus; HIV, human immunodeficiency virus; NA, not applicable; NTS, nontyphoid Salmonella; POS, prospective observational study; SIRS, systemic inflammatory response syndrome. Not differentiated between CA and nosocomial infections, but because of a community-based study design all BSIs are presumed to be CA.
g Criteria for a prospective study were not met, because patients were selected after a blood culture turning positive. [25] . Likewise, the pediatric study of Musiime and colleagues described a significant reduction in bacterial BSI after using ART for >1 year (rate ratio, 0.02) [2, 14, 25, 26, 43] .
Causative Pathogens in HIV-Infected Patients
The patterns of causative bacteria found in HIV patients with BSI differed by geographical region (Figure 4 , Twelve prospective studies (all African studies, except for 1 Asian study) provided comparative data on pathogens found in HIV-positive and -negative study participants [2, 15-17, 20, 25, 26, 29, 33, 37, 39, 41] . In all studies combined, HIV patients with BSI had an increased risk of presenting with NTS compared to HIV-negative patients with BSI (OR, 6.59 [95% CI, 3.70-11.71]; Table 5, Figure 5 ). In contrast, 3 [5, 20, 39] . For other pathogens, no significant differences were reported.
Risk Factors for the Development of CA Bacterial BSI Infections in HIV Patients
Reported factors associated with bacterial BSI in HIV patients were mainly related to the level of immunosuppression. However, information on this topic was limited and results varied between studies. For instance, only 5 of the selected studies compared CD4 counts in HIV patients with and without bacterial BSI [2, 14, 25, 26, 43] . One of these 5, a hospital-based study in the United States, described low CD4 counts in all hospitalized HIV patients, but found no significant difference in patients with and without BSIs [14] . Grant et al described that, among HIV patients admitted to an infectious disease unit, those with septicemia, toxoplasmosis, and tuberculosis had the lowest CD4 counts with an average of 58 cells/ µL [2] . In addition, a Ugandan community-based cohort study described a 7-fold increased incidence of bacterial BSI in HIVinfected patients with CD4 counts <200 cells/µL compared to those with a CD4 count ≥500 cells/µL [25] . Likewise, Meremo et al found significantly lower CD4 counts in HIV patients with bacteremia compared to those without BSI (median, 28 vs 88 cells/µL; P = .01) [26] . In contrast, Musiime et al found no difference in CD4 counts between HIV-positive children with or without BSI (median, 394 vs 389 cells/mL; P = .48) [43] .
Outcome of Bacterial BSI in HIV Patients
Data on mortality rates are summarized in Table 6 . Globally, the mortality rate lies between 7%-46%, but 1 retrospective study in Thailand reported an exceptionally low mortality rate of 0.7% [27] . When stratified by region, mortality rates are 16%-18% in Europe and the United States, 25%-43% in Asia a Criteria for a prospective study were not met, because patients were selected after a blood culture turning positive.
b An additional 51.8% received monotherapy, but for the purpose of this comparison, we only considered patients on combination ART as effectively treated. In the pre-ART period, monotherapy was no longer in use.
c Comparing the first 3 months on ART with ≥12 months on ART.
d Data not stratified by community-acquired and nosocomial infection, but given the scarcity of data on the impact of ART on BSI in children, this article was selected.
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DISCUSSION
Although our study aimed to provide a global view of the relative risk to present to healthcare services with CA bacterial BSI in HIV patients, we only identified prospective case-control studies in Africa, combined with 1 Asian study, probably reflecting the high burden of HIV in many African countries.
(OR, 2.48 [95% CI, 2.10-2.93] in adults and OR, 1.95 [95% CI, 1.61-2.37], in children). This increased risk is related to the level of immunosuppression, as low CD4 counts are cited as a major risk factor [25, 26] . The introduction of ART brought a reduction in bacterial BSIs in studies from Africa, Europe, and the United States (rate ratios, 0.02-0.63) [24, 25, 28, 36, 43] . Information on pathogens causing CA bacterial BSIs in HIV-positive patients was available worldwide. Overall NTS, S.
pneumoniae, E. coli, and S. aureus dominate, but frequency differs by region. We found a remarkably low prevalence of S. pneumoniae (0.8%) infections in Asian HIV patients. Similarly, a review on hospitalized Asian adults with CA BSI found 0.8% S. pneumoniae infections [44] . The authors ascribe this to a relatively low number of HIV-infected individuals in the Asian population. However, we demonstrate that S. pneumoniae is also uncommon in Asian HIV patients. Possible explanations are more widespread use of antibiotic treatment before presentation to healthcare services in this region [44] , or a true difference in geographic distribution of this pathogen. In Europe and the United States, as well as in Africa, the main pathogen is S. pneumoniae (22.8%-58.5%). In Africa, NTS is the second most prominent isolate, whereas S. aureus is more common in the United States and Europe, possibly due to higher rates of intravenous drug use as a risk factor for HIV infection. Culture techniques were largely similar between studies, and therefore are unlikely to explain regional differences in causative pathogens. Studies comparing pathogens according to HIV status were limited to the African region, supplemented by 1 Asian Figure 4 . Geographic distribution of selected studies and main pathogens. Percentages were obtained by analyzing in aggregate all studies that reported on each specific pathogen. Abbreviation: NTS, nontyphoid Salmonella.
study. Within these regions, our findings support the previously described increased risk of HIV-infected patients to develop invasive NTS infections [45, 46] . An increased risk of developing invasive pneumococcal disease has also been described in both adults and children with HIV [6, 47, 48] . For example, in a cohort of Kenyan sex workers, a relative risk of 17.8% to develop invasive pneumococcal infection was found [6] . However, in our grouped analysis the trend toward more infections with S. pneumoniae does not reach statistical significance (OR, 1.45 [95% CI, .97-2.17]) [2, 16, 17, 20, 27, 33, 37, 39, 41] . This discrepancy may be explained by the fact that we mainly included hospital-based studies, whereas increased rates of pneumococcal infection are reported in community-based studies. The significantly decreased risk to develop Salmonella Typhi BSI among HIV patients, as described in 2 studies of Crump et al [20, 39] , is confirmed by our review (OR, 0.11 [95% CI, .06-.22]). Possibly, a difference in immune response against Salmonella Typhi in HIV-infected patients results in absence of clinical symptoms, preventing hospital presentation [20, 49] . Alternatively, early mortality may be increased among HIV patients. However, this hypothesis seems unlikely, because case reports on this subject describe a long-lasting chronic illness, rather than fulminant disease [50, 51] . For Europe and the United States, we can only compare the main pathogens found in our review (S. pneumoniae, S. aureus, and E. coli) with the ones found in the general population. In the United States, similar prevalences have been described for S. pneumoniae, S. aureus, and E. coli [52] , but the high rate of Salmonella species infections appears specific for HIV-infected patients. Information on CA bacterial isolates in HIV-positive children is highly limited. Only 2 African studies provided comparative data on this subject [39, 41] . With the exception of Salmonella Typhi, bacterial isolates from HIV patients in these studies did not differ from the HIV-negative control groups and were in agreement with the ones found in the review by Reddy et al [7] . The high rate of coagulase-negative Staphylococcus isolates in both HIV-positive and HIV-negative children compared to other studies is most likely explained by the presence of contaminants. Based on the limited data available, the pathogens found in children appear to be more related to age than to HIV status.
Mortality rates vary greatly between studies, probably due to differences in clinical state at admission. Generally, mortality of BSI in HIV-infected patients is 7%-46%. The rate of 0.7% reported by Mootsikapun is exceptionally low [27] . This study described good sensitivity to antibiotics as a cause, but this is unlikely to be a sufficient explanation. Rather, the results may be related to a limited severity of illness at the time of blood culture. Overall, the mortality rates in our selected studies are compatible with previously described rates of 15%-45% in patients in the United States with sepsis and septic shock, respectively [53] . Other studies in patients with severe sepsis and septic shock have demonstrated excess mortality in HIV patients [54, 55] . For example, a study on septic shock in a French ICU reported a mortality rate of 46% in HIV-negative patients versus 93% in the HIV-positive group [54] . However, in our selected studies no significant differences were found [18, 27, 41] .
Limitations
There are some limitations to the extent to which the results of this review can be generalized. First, hospital type and study period varied widely. Hence, analyzing the differences in prevalence and causative pathogens in aggregate may not do justice to the actual situation. Second, studies are limited to a few sites, and by grouping them by region we cannot represent the local importance of certain pathogens, especially those isolated in smaller studies. Third, there may be a selection bias toward studies that show a difference in prevalence of CA BSI between HIV-positive and HIV-negative patients. Studies that found no difference may be less likely to stratify their results by HIV status. Also, in selected retrospective studies, for determining the prevalence of specific pathogens, the impact of ART, and outcome, inclusion criteria may have varied and our results may be biased to HIV patients with more severe illness who were thus more likely to be tested for HIV by attending physicians. However, as data on this subject are very limited, especially in regions with a low HIV prevalence such as Europe and the United States, we chose to also include retrospective articles. ART compliance and virological suppression were not reported in studies used for this review; therefore, their influence on the incidence of bacterial BSIs could not be determined.
CONCLUSIONS
Information on CA bacterial BSIs in HIV patients is scarce. Based on predominantly African studies, we report that HIV patients have an increased case fraction of CA BSI when presenting to healthcare services, compared to HIV-negative patients. This difference is especially caused by NTS infections, although regional differences clearly exist. Data from several regions indicate that the use of ART reduces the prevalence of CA BSI in HIV-infected patients. Our survey represents the first systematic review on this topic, and further research is needed to monitor current and future trends in incidence and causative pathogens of CA BSIs in HIV patients.
